Abstract
There has been an increase in understanding molecular biology of malignant pleural mesothelioma. This resulted in more clinical trials of novel therapeutic approaches. The more conventional systemic treatments for malignant mesothelioma are based on the use of Cisplatin and Pemetrexed. The newer agents such as vorinostat an Histone deacetylase inhibitor, focal adhesion kinase inhibitor Defactinib, mTOR inhibitor Everolimus, Bevacizumab a monoclonal antibody directed against Vascular Endothelial Growth Factor, immune check-point inhibitors, mesothelin targeted antibodies, Amatuximab have been investigated for their potential role in treatment of malignant mesothelioma. The role of radiation therapy in the curative treatment of malignant pleural mesothelioma has not been conclusively determined. In this review we will discuss the application of both radical and palliative radiotherapy in the context of managing of malignant mesothelioma.
Keywords: Chemotherapy, malignant mesothelioma, radiotherapy.
Current Respiratory Medicine Reviews
Title:The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Volume: 12 Issue: 3
Author(s): Michael Lind, Rachael Barton, Andrzej Wieczorek, Mahmoud Loubani and Jack A. Kastelik
Affiliation:
Keywords: Chemotherapy, malignant mesothelioma, radiotherapy.
Abstract: There has been an increase in understanding molecular biology of malignant pleural mesothelioma. This resulted in more clinical trials of novel therapeutic approaches. The more conventional systemic treatments for malignant mesothelioma are based on the use of Cisplatin and Pemetrexed. The newer agents such as vorinostat an Histone deacetylase inhibitor, focal adhesion kinase inhibitor Defactinib, mTOR inhibitor Everolimus, Bevacizumab a monoclonal antibody directed against Vascular Endothelial Growth Factor, immune check-point inhibitors, mesothelin targeted antibodies, Amatuximab have been investigated for their potential role in treatment of malignant mesothelioma. The role of radiation therapy in the curative treatment of malignant pleural mesothelioma has not been conclusively determined. In this review we will discuss the application of both radical and palliative radiotherapy in the context of managing of malignant mesothelioma.
Export Options
About this article
Cite this article as:
Lind Michael, Barton Rachael, Wieczorek Andrzej, Loubani Mahmoud and Kastelik A. Jack, The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma, Current Respiratory Medicine Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573398X12666160919115534
DOI https://dx.doi.org/10.2174/1573398X12666160919115534 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Chronic obstructive pulmonary disease (COPD) from childhood to adulthood: from the past to the future
Chronic obstructive pulmonary disease (COPD) is one of the three leading causes of death worldwide, with a major prevalence in low- and middle-income countries, resulting in a high social and economic cost. It is a heterogeneous respiratory disease, treatable and preventable, that causes persistent and often progressive airway obstruction in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
One-pot Synthesis and its Practical Application in Pharmaceutical Industry
Current Organic Synthesis Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
Current Pharmaceutical Design Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Epithelioid Mesothelioma of Peritoneum Masquerading as Peritoneal Carcinomatosis
Current Medical Imaging Multimodal HDAC Inhibitors with Improved Anticancer Activity
Current Cancer Drug Targets Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures
Recent Patents on Anti-Cancer Drug Discovery Pulmonary Surfactant Proteins A and D: Innate Immune Functions and Biomarkers for Lung Diseases
Current Pharmaceutical Design Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design An <i>In vivo</i> Immunohistochemical Study on MacroH2A.1 in Lung and Lymph-Node Tissues Exposed to an Asbestiform Fiber
Current Molecular Medicine Potential of Taming MicroRNA on Driver Seat to Control Mitochondrial Horses in Breast Carcinoma
MicroRNA Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design Epigenetics of Virus-Induced Tumors: Perspectives for Therapeutic Targeting
Current Pharmaceutical Design Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Current Cancer Therapy Reviews To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets